Deacon's Challenge No 106 - Answer

A serum from a patient with prolactinoma has a prolactin value beyond the analytical range of the assay. The endocrinologists have asked for a numerical value to provide a baseline for monitoring the patient. In an attempt to preserve the matrix upon dilution, 0.1 mL of the sample is mixed with 2.0 mL of a serum from another patient which has a prolactin value of 400 mU/L. If the assay result for the mixture is 1050 mU/L, calculate the prolactin concentration in the serum from the prolactinoma patient.

First calculate the contribution from the base (i.e. normal) sample:

Expected prolactin contribution from base sample =

Serum prolactin (mU/L) x Vol base sample (mL) Total volume (mL)

Substitute: Base sample prolactin = 400 mU/L Base sample volume = 2 mL

Total volume = Vol base sample + Vol prolactinoma sample = 2 + 0.1 = 2.1 mL

 $400 \times 2 = 381 \text{ mU/L}$ (to 3 sig figs) Expected contribution from base sample =

Next calculate the prolactin concentration in the diluted prolactinoma sample:

Prolactin in diluted prolactinoma sample

Measured total prolactin - Expected prolactin contribution from base sample

= 1050 - 381 = 669 mU/L

Finally correct for the dilution of the prolactinoma sample:

Prolactin in undiluted prolactinoma sample = Prolactin in diluted sample x Total vol (mL) Vol prolactinoma sample (mL)

> 669 x 2.1 0.1

14,000 mU/L (to 3 sig figs)

Question 107

Your paediatricians wish to screen a population for the presence of a rare disease which has a prevalence of 1 in 2000. However, the preferred screening test, for which the sensitivity and specificity are both 99% is prohibitively expensive so you suggest a two step strategy employing a preliminary inexpensive screening test which has a sensitivity of 99% but a specificity of only 96%. The preferred (secondary) test will only be applied to those samples yielding a positive result in the preliminary test. The paediatricians have asked you to calculate:

- a) The prevalence of disease in the population giving a positive result to the preliminary screening test.
- The percentage of patients with disease who will be successfully identified using this strategy.
- The percentage of patients identified as having the disease by this strategy which are false positives.